Parent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from Turkey
OBJECTIVE: Medikinet retard® is a nonosmotic, extended-release formulation of Methylphenidate (MPH) and has been used in Turkey for the last 4–5 years. The aim of our study is to compare the efficacy on functionality of Medikinet retard® and Concerta® and their adverse events. METHODS: Participants...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AVES
2019-10-01
|
| Series: | Psychiatry and Clinical Psychopharmacology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/24750573.2019.1609153 |
| _version_ | 1797907258890256384 |
|---|---|
| author | Merve Cikili Uytun Fatih Hilmi Çetin Zehra Babadağı |
| author_facet | Merve Cikili Uytun Fatih Hilmi Çetin Zehra Babadağı |
| author_sort | Merve Cikili Uytun |
| collection | DOAJ |
| description | OBJECTIVE: Medikinet retard® is a nonosmotic, extended-release formulation of Methylphenidate (MPH) and has been used in Turkey for the last 4–5 years. The aim of our study is to compare the efficacy on functionality of Medikinet retard® and Concerta® and their adverse events. METHODS: Participants were referred to the Kayseri Training and Research Hospital and followed up there between August 2016 and June 2018. This study design is a 16-week prospective trial, each child received 16 weeks of OROS-MPH or MPH-ER. A total of 103 children were enrolled in the study, but only 70 children (n = 35 concerta, n = 35 medikinet retard) completed the study. Weiss Functional Impairment Rating Scale-Parent Report Form (WFIRS-P) and Barkley Side Effect Rating Scale (BSERS) were used for assessment. RESULTS: In both treatment groups, children improved significantly over time, both in intensity and in the number of problems. Regarding the social problems, Medikinet retard® was superior to the Concerta in terms of effects. The side effects of insomnia and euphoria were seen more common in the Concerta® group than the Medikinet retard®. Additionally, the mean severity scores of euphoria were shown higher in the Concerta® group than the Medikinet retard. CONCLUSION: From this study, we concluded that Medikinet retard® is also an effective and safety MPH formulation. |
| first_indexed | 2024-04-10T10:33:36Z |
| format | Article |
| id | doaj.art-ccfc3c63ec8a4eb2af651f391bbee8f3 |
| institution | Directory Open Access Journal |
| issn | 2475-0581 |
| language | English |
| last_indexed | 2024-04-10T10:33:36Z |
| publishDate | 2019-10-01 |
| publisher | AVES |
| record_format | Article |
| series | Psychiatry and Clinical Psychopharmacology |
| spelling | doaj.art-ccfc3c63ec8a4eb2af651f391bbee8f32023-02-15T16:20:58ZengAVESPsychiatry and Clinical Psychopharmacology2475-05812019-10-0129472272910.1080/24750573.2019.16091531609153Parent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from TurkeyMerve Cikili Uytun0Fatih Hilmi Çetin1Zehra Babadağı2Ankara UniversitySelcuk UniversityKayseri Training and Research HospitalOBJECTIVE: Medikinet retard® is a nonosmotic, extended-release formulation of Methylphenidate (MPH) and has been used in Turkey for the last 4–5 years. The aim of our study is to compare the efficacy on functionality of Medikinet retard® and Concerta® and their adverse events. METHODS: Participants were referred to the Kayseri Training and Research Hospital and followed up there between August 2016 and June 2018. This study design is a 16-week prospective trial, each child received 16 weeks of OROS-MPH or MPH-ER. A total of 103 children were enrolled in the study, but only 70 children (n = 35 concerta, n = 35 medikinet retard) completed the study. Weiss Functional Impairment Rating Scale-Parent Report Form (WFIRS-P) and Barkley Side Effect Rating Scale (BSERS) were used for assessment. RESULTS: In both treatment groups, children improved significantly over time, both in intensity and in the number of problems. Regarding the social problems, Medikinet retard® was superior to the Concerta in terms of effects. The side effects of insomnia and euphoria were seen more common in the Concerta® group than the Medikinet retard®. Additionally, the mean severity scores of euphoria were shown higher in the Concerta® group than the Medikinet retard. CONCLUSION: From this study, we concluded that Medikinet retard® is also an effective and safety MPH formulation.http://dx.doi.org/10.1080/24750573.2019.1609153methylphenidateconcertamedikinet retardadhdsocialfunctionality |
| spellingShingle | Merve Cikili Uytun Fatih Hilmi Çetin Zehra Babadağı Parent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from Turkey Psychiatry and Clinical Psychopharmacology methylphenidate concerta medikinet retard adhd social functionality |
| title | Parent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from Turkey |
| title_full | Parent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from Turkey |
| title_fullStr | Parent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from Turkey |
| title_full_unstemmed | Parent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from Turkey |
| title_short | Parent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from Turkey |
| title_sort | parent reported social problems and clinician evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations a prospective naturalistic study from turkey |
| topic | methylphenidate concerta medikinet retard adhd social functionality |
| url | http://dx.doi.org/10.1080/24750573.2019.1609153 |
| work_keys_str_mv | AT mervecikiliuytun parentreportedsocialproblemsandclinicianevaluatedadverseeffectsmaybedifferentiallyaffectedbydifferingextendedreleasemethylphenidateformulationsaprospectivenaturalisticstudyfromturkey AT fatihhilmicetin parentreportedsocialproblemsandclinicianevaluatedadverseeffectsmaybedifferentiallyaffectedbydifferingextendedreleasemethylphenidateformulationsaprospectivenaturalisticstudyfromturkey AT zehrababadagı parentreportedsocialproblemsandclinicianevaluatedadverseeffectsmaybedifferentiallyaffectedbydifferingextendedreleasemethylphenidateformulationsaprospectivenaturalisticstudyfromturkey |